Purple Biotech (PPBT) Notes Payables (2017 - 2020)

Purple Biotech (PPBT) has 4 years of Notes Payables data on file, last reported at $24.4 million in Q2 2020.

• On a quarterly basis, Notes Payables rose 895.63% year-over-year to $24.4 million in Q2 2020; TTM through Jun 2020 was $24.4 million, a 895.63% increase from a year earlier, with the FY2018 full-year figure at $554000.0, down 72.47% from the prior year.
• Notes Payables for Q2 2020 stood at $24.4 million, up from $2.5 million in the prior quarter.
• Over the last five years, Notes Payables for PPBT reached as high as $24.4 million in Q2 2020 and fell as low as $554000.0 in Q4 2018.
• Historically, Notes Payables has averaged $5.8 million across 4 years, with a median of $2.2 million in 2017.
• Across the five-year window, Notes Payables plunged 72.47% in 2018 and soared 895.63% in 2020, its largest moves.
• Year by year, Notes Payables stood at $2.0 million in 2017, then plunged by 72.47% to $554000.0 in 2018, then surged by 342.42% to $2.5 million in 2019, then surged by 895.63% to $24.4 million in 2020.
• Per Business Quant data, the three most recent Notes Payables figures were $24.4 million in Q2 2020, $2.5 million in Q2 2019, and $554000.0 in Q4 2018.